Lexeo Therapeutics, Inc.

Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy. The company is also developing LX2022, a gene therapy candidate, which is in preclinical trial to deliver a functional TNNI3 gene to myocardial cells to treat a distinct form of hypertrophic cardiomyopathy. In addition, it is developing LX1001, LX1020, and LX1021, an AAVrh10-based gene therapy candidate, which has completed phase 1/2 clinical trial for the treatment of APOE4-associated Alzheimer's disease. The company has a license agreement with Cornell University to conduct the Phase 1/2 clinical trial of LX1001, as well as support the development of the LX1004 program; a research collaboration agreement with Cornell University to conduct preclinical research to develop the licensed technology; and third license agreement which obtained certain rights for FA cardiomyopathy, including rights to current and future clinical data from an ongoing Cornell University investigator-initiated Phase 1A trial of a gene therapy candidate. The company was founded in 2017 and is headquartered in New York, New York.

Lexeo Therapeutics, Inc.는 임상 단계 유전의학 기업으로, 미국 내 미충족 의료 수요가 높은 유전성 및 후천성 질환에 주력하고 있습니다. 당사의 제품 파이프라인에는 프리드리히 운동실조 심근병증 치료를 위한 AAVrh10 기반 유전자 치료제 후보물질인 LX2006이 포함되어 있으며, 현재 임상 1/2상 시험을 진행 중입니다. 또한, PKP2-ACM 치료를 위해 기능성 plakophilin-2 (PKP2) 유전자를 심근에 전달하는 AAVrh10 기반 유전자 치료제 후보물질인 LX2020은 임상 1/2상 단계에 있습니다. 그리고